Myelin oligodendrocyte glycoprotein 35-55-specific T-cell receptor (MOG35-55-specific TCR)

The Myelin oligodendrocyte glycoprotein 35-55-specific T-cell receptor is a membrane-bound heterodimeric protein complex primarily expressed on the surface of autoreactive CD4+ T lymphocytes. It specifically recognizes the immunodominant 35-55 amino acid fragment of the myelin oligodendrocyte glycoprotein (MOG) when presented by major histocompatibility complex (MHC) class II molecules, such as I-Ab in mice or HLA-DR2 in humans (PubMed: 10820258). This recognition event is a critical driver of neuroinflammation and demyelination in experimental autoimmune encephalomyelitis (EAE), the primary animal model for multiple sclerosis (MS) (PubMed: 15634887). Upon binding to the MOG35-55 peptide, the TCR triggers a signaling cascade that leads to T-cell proliferation and the secretion of pro-inflammatory cytokines like IFN-gamma and IL-17, which facilitate the destruction of the myelin sheath in the central nervous system (UniProt: P06314). Therapeutic strategies targeting this receptor aim to restore immune homeostasis by inducing antigen-specific tolerance, anergy, or the selective elimination of these pathogenic T-cell clones without compromising the broader immune system (PubMed: 23740477). Current research focuses on using soluble peptide fragments, tolerogenic dendritic cells, or engineered regulatory T cells to modulate the activity of these MOG-specific autoreactive cells.

Other names

MOG35-55 TCRMOG-specific T-cell receptorMyelin oligodendrocyte glycoprotein peptide 35-55-specific T-cell receptorAutoreactive MOG-specific TCR

Induction of antigen-specific immune tolerance, T-cell anergy, or selective depletion of autoreactive T-cell clones through the presentation of the MOG35-55 epitope in a non-immunogenic context (PubMed: 23740477, 15634887).